Insider · CIK 0002050172

Bernstein Harold

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0002050172

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-01	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−16.1K sh	—	—	144,521
2026-10-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−16.1K sh	$26.93	−$435K	0
2026-10-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+16.1K sh	$10.42	+$168K	16,141
2026-09-04	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−9,705 sh	$26.22	−$255K	0
2026-09-03	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−5,130 sh	$26.01	−$133K	9,764
2026-09-03	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−59 sh	$25.78	−$1,521.02	9,705
2026-09-02	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−625 sh	$27.12	−$17K	14,894
2026-09-02	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−4,481 sh	$26.38	−$118K	15,519
2026-09-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+20K sh	—	—	20,000
2026-09-01	MAZEMaze Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−20K sh	—	—	20,000
2026-09-01	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−16.1K sh	—	—	160,662
2026-09-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−16.1K sh	$26.36	−$426K	0
2026-09-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+16.1K sh	$10.42	+$168K	16,141
2026-08-13	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−16.1K sh	—	—	176,803
2026-08-13	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−16.1K sh	$27.61	−$446K	0
2026-08-13	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+16.1K sh	$10.42	+$168K	16,142
2026-07-01	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−14.6K sh	—	—	192,945
2026-07-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+14.6K sh	$10.42	+$152K	14,609
2026-07-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−13.4K sh	$29.86	−$400K	1,200
2026-07-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−1,200 sh	$30.34	−$36.4K	0
2026-06-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−1,600 sh	$26.36	−$42.2K	0
2026-06-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+14.9K sh	$10.42	+$155K	14,853
2026-06-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−13.3K sh	$25.57	−$339K	1,600
2026-06-01	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−14.9K sh	—	—	207,554
2026-05-14	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−15K sh	$26.22	−$393K	0
2026-05-14	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+15K sh	$10.42	+$156K	15,000
2026-05-14	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−15K sh	—	—	222,407
2026-04-01	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+15K sh	$10.42	+$156K	15,000
2026-04-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−11.4K sh	$29.24	−$332K	3,648
2026-04-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−3,348 sh	$30.06	−$101K	300
2026-04-01	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−300 sh	$31.07	−$9,320.01	0
2026-04-01	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−15K sh	—	—	237,407
2026-03-20	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−15K sh	—	—	252,407
2026-03-20	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−6,161 sh	$48.20	−$297K	8,839
2026-03-20	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+15K sh	$10.42	+$156K	15,000
2026-03-20	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−3,795 sh	$49.32	−$187K	5,044
2026-03-20	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−5,044 sh	$50.02	−$252K	0
2026-03-10	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−29.7K sh	$50.45	−$1.5M	348
2026-03-10	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+30K sh	$10.42	+$313K	30,000
2026-03-10	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−30K sh	—	—	267,407
2026-03-10	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−348 sh	$51.02	−$17.8K	0
2026-03-02	MAZEMaze Therapeutics, Inc. · Restricted Stock UnitsA Award	President, R&D & CMO	AAward	+24K sh	—	—	24,000
2026-03-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	President, R&D & CMO	AAward	+48K sh	—	—	48,000
2026-02-02	MAZEMaze Therapeutics, Inc.M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	+15K sh	$10.42	+$156K	15,000
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−5,936 sh	$46.37	−$275K	100
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−8,364 sh	$45.89	−$384K	6,036
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−600 sh	$44.20	−$26.5K	14,400
2026-02-02	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	President, R&D & CMO	MExercise/Conversion	−15K sh	—	—	297,407
2026-02-02	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−100 sh	$47.23	−$4,723	0
2026-01-07	MAZEMaze Therapeutics, Inc.S Sale	President, R&D & CMO	SSale	−25.2K sh	$40.20	−$1.01M	0

Recent filings

Accepted (ET)
Oct 24
Bernstein Harold0002050172-26-000038
SEC(opens sec.gov)
Sep 84
Bernstein Harold0002050172-26-000036
SEC(opens sec.gov)
Sep 44
Bernstein Harold0002050172-26-000034
SEC(opens sec.gov)
Sep 34
Bernstein Harold0002050172-26-000032
SEC(opens sec.gov)
Aug 144
Bernstein Harold0002050172-26-000028
SEC(opens sec.gov)
Jul 24
Bernstein Harold0002050172-26-000025
SEC(opens sec.gov)

Companies

Maze Therapeutics, Inc.President, R&D & CMOMAZE

Address

C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300

SOUTH SAN FRANCISCO, CA, 94080